Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Disc Medicine (IRON)
NASDAQ:IRON
IRON Stock Chart & Stats
Day’s Range― - ―
52-Week Range$25.60 - $77.60
Previous CloseN/A
Volume41.94K
Average Volume (3M)416.00K
Market Cap
$1.87B
Enterprise Value$985.46M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.81
Next Earnings
Mar 28, 2025EPS Estimate
-1.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.97
Shares Outstanding34,290,913
10 Day Avg. Volume275,356
30 Day Avg. Volume416,001
Standard Deviation0.22
R-Squared0.03
Alpha-0.00398
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-23.40
P/FCF Ratio0.00
Enterprise Value/Market Cap0.53
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-9.85K
Enterprise Value/Ebitda-7.90
Forecast
1Y Price Target
$94.82Price Target Upside74.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
---
Disc Medicine News
PremiumCompany Announcements
Disc Medicine Advances Bitopertin Trial for EPP
PremiumCompany Announcements
Disc Medicine Highlights 2025 Strategy and Financial Updates---
Bulls Say, Bears Say
Bulls Say
Clinical ProgressThe ongoing clinical progress and positive portfolio updates continue to support the advancement of Disc Medicine's drug development initiatives.
Clinical Trial DesignDisc Medicine Inc has reached alignment with the FDA on the design of the Phase 3 APOLLO confirmatory trial for their bitopertin drug.
Regulatory ApprovalThe FDA alignment suggests potential for accelerated approval for bitopertin, allowing it to reach the market faster and with higher probability.
Bears Say
Commercialization RisksCommercial risks are present since Disc has never commercialized a product and DISC-0974 and MTX-003 are targeting competitive markets.
Market CompetitionThe only FDA-approved treatment for EPP, Scenesse, is only available through tightly controlled distribution in the US and has limited efficacy.
Regulatory RisksKey risks include regulatory approval since none of Disc's assets are approved.
---
Ownership Overview
27.10% Insiders
12.33% Mutual Funds
33.87% Other Institutional Investors
19.10% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
IRON FAQ
What was Disc Medicine’s price range in the past 12 months?
Disc Medicine lowest stock price was $25.60 and its highest was $77.60 in the past 12 months.
What is Disc Medicine’s market cap?
Disc Medicine’s market cap is $1.87B.
When is Disc Medicine’s upcoming earnings report date?
Disc Medicine’s upcoming earnings report date is Mar 28, 2025 which is in 35 days.
How were Disc Medicine’s earnings last quarter?
Disc Medicine released its earnings results on Nov 12, 2024. The company reported -$0.89 earnings per share for the quarter, beating the consensus estimate of -$1.037 by $0.147.
Is Disc Medicine overvalued?
According to Wall Street analysts Disc Medicine’s price is currently Undervalued.
Does Disc Medicine pay dividends?
Disc Medicine does not currently pay dividends.
What is Disc Medicine’s EPS estimate?
Disc Medicine’s EPS estimate is -1.11.
How many shares outstanding does Disc Medicine have?
Disc Medicine has 34,290,913 shares outstanding.
What happened to Disc Medicine’s price movement after its last earnings report?
Disc Medicine reported an EPS of -$0.89 in its last earnings report, beating expectations of -$1.037. Following the earnings report the stock price went down -4.972%.
Which hedge fund is a major shareholder of Disc Medicine?
Currently, no hedge funds are holding shares in IRON
---
Disc Medicine Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$94.82 (74.11% Upside)
$94.82 (74.11% Upside)
Blogger Sentiment
Bullish
IRON Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 20.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-17.38%
12-Months-Change
Fundamentals
Return on Equity
-25.03%
Trailing 12-Months
Asset Growth
31.51%
Trailing 12-Months
Company Description
Disc Medicine
FS Development Corp is a blank check company.
---
IRON Stock 12 Month Forecast
Average Price Target
$94.82
▲(74.11% Upside)
Technical Analysis
Best Analysts Covering IRON
1 Year
1 Year Success Rate
10/15 ratings generated profit
1 Year Average Return
+13.12%
reiterated a buy rating last month
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +13.12% per trade.
---